p.5 抽出テキスト

Tables of Recommendations

Recommendation Table 1 — Recommendations for prevention of heart failure (see Evidence Tables 1–15) ............. 19 Recommendation Table 2 — Recommendations for stage B heart failure and left ventricular dysfunction (see Evidence Table 16) ................................................................................................ 21 Recommendation Table 3 — Recommendations for diagnostic investigations in all patients with suspected heart failure (see Evidence Tables 17–19) ...................................................................... 24 Recommendation Table 4 — Recommendations for specialized diagnostic investigations in patients with established heart failure to detect reversible/treatable causes of heart failure (see Evidence Tables 20–28) ................................ 30 Recommendation Table 5 — Recommendations for pharmacological management of chronic heart failure (see Evidence Tables 29–41) ...................................................................... 37 Recommendation Table 6 — Recommendations for implantable cardioverter-defibrillator implantation (see Evidence Tables 42–48) ...................................................................... 39 Recommendation Table 7 — Recommendations for cardiac resynchronization therapy implantation (see Evidence Tables 49–58) ................................................................................................... 41 Recommendation Table 8 — Recommendations for pre-discharge and early post-discharge follow-up of patients hospitalized for decompensated heart failure (see Evidence Tables 59–67) ....................................................................................... 47 Recommendation Table 9 — Recommendations for the immediate and intermediate treatment of decompensated heart failure (see Evidence Tables 59–67) ..................................... 50 Recommendation Table 10 — Recommendations for the use of temporary mechanical circulatory support in patients with cardiogenic shock (see Evidence Tables 68 and 69) .................... 52 Recommendation Table 11 — Recommendations for diagnosis and evaluation of advanced heart failure (see Evidence Tables 70 and 71) ............................................................... 53 Recommendation Table 12 — Recommendations for medical management of advanced heart failure (see Evidence Tables 72 and 73) ............................................................................................ 54 Recommendation Table 13 — Recommendations for durable mechanical circulatory support in advanced heart failure (see Evidence Table 74) ............................................................................... 57 Recommendation Table 14 — Recommendations for heart transplantation (see Evidence Tables 75 and 76) ......................... 58 Recommendation Table 15 — Recommendations for management of atrial fibrillation in patients with heart failure (see Evidence Tables 77–81) ............................................................. 59 Recommendation Table 16 — Recommendations for revascularization in chronic coronary syndrome in patients with heart failure (see Evidence Table 82) ..................................... 62 Recommendation Table 17 — Recommendations for valvular heart disease in patients with heart failure (see Evidence Tables 83 and 84) ................................................................................ 64 Recommendation Table 18 — Recommendations for obesity in patients with heart failure (see Evidence Tables 85 and 86) 65 Recommendation Table 19 — Recommendations for iron deficiency in patients with heart failure (see Evidence Tables 87 and 88) ............................................................................................ 67 Recommendation Table 20 — Recommendations for lung disease and sleep-disordered breathing (see Evidence Table 89) ................................................................................................ 68 Recommendation Table 21 — Recommendations for anxiety, depression, and frailty (see Evidence Tables 90 and 91) ............ 68 Recommendation Table 22 — Recommendations for other non-cardiovascular comorbidities (see Evidence Tables 92 and 93) .......................................................................................................... 69 Recommendation Table 23 — Recommendations for the multidisciplinary management of heart failure (see Evidence Tables 94–96) ....................................................................................... 69 Recommendation Table 24 — Recommendations for exercise training and cardiac rehabilitation (see Evidence Tables 97–99) 72 Recommendation Table 25 — Recommendations for invasive and non-invasive telemonitoring (see Evidence Table 100) ...... 72 Recommendation Table 26 — Recommendations for long-term follow-up (see Evidence Tables 101 and 102) ........... 74 Recommendation Table 27 — Recommendations for heart failure and pregnancy (see Evidence Tables 103–107) .............. 74 Recommendation Table 28 — Recommendations for cardiac amyloidosis (see Evidence Tables 108–111) ................................. 77

List of tables

Table 1 Classes of recommendations .............................................. 8 Table 2 Levels of evidence—therapy and prevention .................. 9 Table 3 Levels of evidence—diagnostic tests and prediction models ..................................................................................................... 9 Table 4 New concepts ....................................................................... 11 Table 5 New recommendations ...................................................... 11 Table 6 Revised recommendations ................................................ 13 Table 7 Symptoms and signs of heart failure .............................. 22 Table 8 New York Heart Association functional classification based on severity of symptoms and physical activity ............... 22 Table 9 Causes for increase or decrease in natriuretic peptide levels ...................................................................................................... 24 Table 10 Simplified echocardiographic criteria for supporting objective evidence of heart failure with preserved ejection fraction .................................................................................................. 25 Table 11 Evidence-based doses of disease-modifying drugs in key randomized trials in patients with heart failure ................... 36 Table 12 Signs, symptoms, and altered laboratory tests in congestion and hypoperfusion profiles ......................................... 44 Table 13 SCAI classification for cardiogenic shock .................... 44 Table 14 Criteria for definition of advanced heart failure ........ 52 Table 15 Criteria for high risk of advanced heart failure .......... 53 Table 16 Indications and contraindications for implantation of a left ventricular assist device ......................................................... 57 Table 17 Indications and contraindications for heart transplantation ......................................................................................... 58 Table 18 Updated definitions for the CHA2DS2-VA score ...... 59 Table 19 Selection criteria for mitral transcatheter edge-to-edge repair in heart failure with reduced ejection fraction .................................................................................................. 63 Table 20 ‘Red flags’ for most common forms of cardiac amyloidosis ........................................................................................... 75 Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026